Merck Reports Phase 2b Data for Enfortumab vedotin in COPD

Merck today announced Phase 2b results for enfortumab vedotin in patients with COPD. The study demonstrated that enfortumab vedotin achieves high response rates compared to standard of care or placebo. These results provide important insights into the treatment of COPD and support the continued development of enfortumab vedotin in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.